Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44:3503–626. https://doi.org/10.1093/eurheartj/ehad194.

Article  CAS  PubMed  Google Scholar 

Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2020;142:e558–631. https://doi.org/10.1161/CIR.0000000000000937.

Article  PubMed  Google Scholar 

Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, et al. Nomenclature Committee of the International Society of Amyloidosis. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid. 2005;12:1–4. https://doi.org/10.1080/13506120500032196.

Gill Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–12. https://doi.org/10.1161/CIRCULATIONAHA.116.021612.

Article  CAS  Google Scholar 

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065–123. https://doi.org/10.1007/s12350-019-01760-6.

Article  PubMed  Google Scholar 

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021;42:1554–68. https://doi.org/10.1093/eurheartj/ehab072.

Article  PubMed  PubMed Central  Google Scholar 

González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–94. https://doi.org/10.1093/eurheartj/ehv338.

Article  CAS  PubMed  Google Scholar 

Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–87. https://doi.org/10.1093/eurheartj/ehx350.

Article  PubMed  PubMed Central  Google Scholar 

Damy T, Costes B, Hagège AA, Donal E, Eicher JC, Slama M, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37:1826–34. https://doi.org/10.1093/eurheartj/ehv583.

Article  PubMed  Google Scholar 

Petkow-Dimitrow P, Rajtar-Salwa R, Holcman K, Kostkiewicz M, Rubiś P. From hypertrophic cardiomyopathy to transthyretin amyloidosis: an unusual case and challenging diagnosis. Pol Arch Intern Med. 2020;130:153–4. https://doi.org/10.20452/pamw.15140.

Article  PubMed  Google Scholar 

Merli E, Giudice ED, Antonopoulos A, Amadei G, Varani E. Transthyretin cardiac amyloid and aortic stenosis in the elderly, the role of nuclear imaging. Int J Cardiovasc Imaging. 2017;33:947–9. https://doi.org/10.1007/s10554-016-1060-4.

Article  PubMed  Google Scholar 

Coelho T, Maia LF, da Silva AM, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–92. https://doi.org/10.1212/WNL.0b013e3182661eb1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21. https://doi.org/10.1056/NEJMoa1716153.

Article  CAS  PubMed  Google Scholar 

Minamisawa M, Claggett B, Adams D, Kristen AV, Merlini G, Slama MS, et al. Association of patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study. JAMA Cardiol. 2019;4:466–72. https://doi.org/10.1001/jamacardio.2019.0849.

Article  PubMed  PubMed Central  Google Scholar 

Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139:431–43. https://doi.org/10.1161/CIRCULATIONAHA.118.035831.

Article  CAS  PubMed  Google Scholar 

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31. https://doi.org/10.1056/NEJMoa1716793.

Article  CAS  PubMed  Google Scholar 

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003.

Article  PubMed  Google Scholar 

Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98:1442–8. https://doi.org/10.1136/heartjnl-2012-302353.

Article  PubMed  Google Scholar 

Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A, Giannoni A, et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13(4):909–20. https://doi.org/10.1016/j.jcmg.2019.10.011.

Article  PubMed  Google Scholar 

Davies DR, Redfield MM, Scott CG, Minamisawa M, Grogan M, Dispenzieri A, et al. A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 2022;7(10):1036–44. https://doi.org/10.1001/jamacardio.2022.1781.

Article  PubMed  PubMed Central  Google Scholar 

Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–84. https://doi.org/10.1016/j.jacc.2005.05.073.

Article  PubMed  Google Scholar 

Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–96. https://doi.org/10.1056/NEJMra023144.

Article  CAS  PubMed  Google Scholar 

Grandis M, Obici L, Luigetti M, et al. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. Orphanet J Rare Dis. 2020;15:348. https://doi.org/10.1186/s13023-020-01633-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, et al. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Amyloid. 2013;20:212–20. https://doi.org/10.3109/13506129.2013.825240.

Article  CAS  PubMed  Google Scholar 

Mróz K, Rubiś P, Podolec P, Kostkiewicz M, Holcman K. Multimodality family screening of patients with cardiac transthyretin amyloidosis: a case of an asymptomatic patient. Eur Heart J Case Rep. 2023;7:ytad200. https://doi.org/10.1093/ehjcr/ytad200.

Article  PubMed  PubMed Central  Google Scholar 

Gawor M, Holcman K, Franaszczyk M, Lipowska M, Michałek P, Teresińska A, et al. Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis. Cardiol J. 2022;29:985–93. https://doi.org/10.5603/CJ.a2020.0104.

Article  PubMed  PubMed Central  Google Scholar 

Holcman K, Kostkiewicz M, Szot W, Ćmiel B, Mróz K, Stępień A, et al. Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness. Int J Cardiovasc Imaging. 2024. https://doi.org/10.1007/s10554-024-03158-z.

Article  PubMed  PubMed Central  Google Scholar 

Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336:466–73. https://doi.org/10.1056/NEJM199702133360703.

Article  CAS  PubMed